Bavarian Biotech Report 2011/2012 (7MB) - Bio M

More documents

Recommendations

Info

Deals, Cooperation, Mergers, FinancingDeals and CooperationIn 2011, the Bavarian Biotech companies have been very active in closing many cooperation deals. Despite the difficulteconomic situation, all Bavarian biotech companies have been doing their homework in finding new partnerships orextending long-term cooperation deals. In the beginning of 2011, Pieris (Weihenstephan) signed an Anticalin® Therapeuticcollaboration with Takeda San Francisco, where Pieris will use its innovative technology platform based on Anticalin scaffoldsto identify new potential candidates for Takeda. A few months later, Pieris announced the signing of a drug developmentcollaboration with Daiichi Sankyo Company Limited. Under this agreement Pieris has received € 7 million uponsigning the collaboration agreement for two targets and will obtain research funding and payments for the achievement ofresearch, preclinical, regulatory and commercial milestones. Altogether, this partnership will be valued with more than€ 100 million per target for Pieris.Another mature biotech company, Micromet agreed on acollaboration with Amgen in July 2011 to develop cancerantibodies that could be worth € 695 million. The collaborationfocused of bispecific T-cell engager (BiTE) antibodiesagainst three solid tumor targets. Amgen decidedonly a few months later, that this technology and pipelineshould be integrated in toto – and bought Micromet inspring 2012 for nearly 1,2 billion US $ (see page 10)!End of July 2011, MorphoSys’ diagnostics unit AbDSerotec started a research and supply cooperation withthe Department of Cancer Immunology and AIDS at theDana-Farber Cancer Institute (DFCI) in Boston. The companyprovides research tools using its proprietary Slonomicstechnology platform; in return AbD Serotecreceives financial compensation and preferred access tocommercialization rights for products generated duringthe collaboration.Altogether, more than ten service collaborations havebeen signed within the Bavarian Biotech Cluster, ofwhich Proteros Biostructures GmbH (Martinsried) hasclosed five service collaborations. In May 2011, e.g.,they signed a collaboration agreement with the InstitutPasteur Korea in the field of infectious diseases byproviding their expertise in structural analysis andX-ray crystallography. In July 2011 they increased theirservice collaborations with AMRI as well as with RigelPharmaceuticals.In January 2011, KINAXO Biotechnologies (Martinsried)started its collaboration with AstraZeneca to supportthe oncology program of AstraZeneca by applyingKINAXO’s technology platform. A couple of months later,KINAXO signed its second collaboration with TakedaPharmaceutical Company Limited Osaka. With thesupport of KINAXO’s PhosphoScout® technology platformTakeda could accelerate its decision making process ondrug efficacy and safety. It was only a few weeks laterthat Evotec AG, Hamburg, bought and integrated Kinaxofor about € 15 Mio.In addition to service collaborations, the Bavarian Biotechcompanies have closed several international marketing,sales and distribution agreements. Particularly MediGene(Martinsried) signed seven new commercialization agreementsfor the commercialization of Veregen ® with internationalpharmaceutical companies. An exclusive licensingand supply agreement with the Canadian companyTriton Pharma Inc. for the supply and commercializationof Veregen ® for the treatment of genital warts in Canadawas closed in April 2011. Triton will be responsible for thedrug approval procedure in Canada. MediGene is entitledto payments totaling up to € 2.1 million upon theachievement of milestones, and will obtain royalties onthe sales revenue generated with Veregen ® in the form ofa double-digit percentage share.Furthermore, Wilex Inc., the 100 percent subsidiary ofWilex AG (München) signed an exclusive co-marketingand distribution agreement with American LaboratoryProducts Company Inc. (Salem, USA) as regards thecommercialization of the Serum HER-2/neu ELISA test,the only FDA-cleared IVD ELISA in North America formonitoring women with metastatic breast cancer.Definiens and Leica Microsystems havestarted their marketing Joint Venture inApril 2011. Both companies will jointlymarket their complementary productsand will be providing commonworkshops and educationalevents.22
Moreover, positive news were published in the year 2011by MorphoSys regarding their three long-term partnerships:The company received an important technologymilestone payment from Novartis after having finishedthe installation of its HuCAL antibody platform at NovartisInstitutes for BioMedical Research in Basel. In September2011, MorphoSys reported that Bayer HealthCarePharmaceuticals had accomplished the next milestone byinitiating a phase I clinical trial with the HuCAL-derivedantibody-drug conjugate BAY 94-9343 in the therapeuticarea of oncology. Furthermore in November 2011, MorphoSysand Shionogi & Co., Ltd. expanded their agreementfor additional three years. This cooperation focuseson MorphoSys’ HuCAL technology and additional proprietarytechnology modules for research in drug discovery.MorphoSys and Shionogi closed the first license agreementin September 2005.By analyzing the different licensing deals during theyear 2011, several Bavarian Biotech companies haveannounced significant deals with international industrypartners. For example, 4SC (Martinsried) and YakultHonsha (Japan) signed an exclusive license agreementfor Japan based on 4SC’soral HDAC Inhibitor Resminostat.Under these terms of agreement, 4SC AG has receivedan upfront payment from Yakult Honsha of € 6 millionand will receive up to € 127 million payable upon achievingspecified milestones including clinical and regulatoryevents in Japan. In addition to milestone payments,Yakult will pay 4SC double-digit royalties linked to productsales of Resminostat, which will also include the APIcosts.Another Bavarian Biotech company, Affectis Pharamceuticals(Martinsried), signed an exclusive licensing agreementwith Merck Serono, Darmstadt, for oral compoundstargeting the P2X7 receptors. Affectis has obtained € 2.4million upfront payment, will receive research fundingand could obtain up to € 277 million in milestones andundisclosed royalties. In addition, the Munich basedWilex (Munich) has granted exclusive US commercialisationrights for RENCAREX ® to Prometheus LaboratoriesInc., San Diego, USA. By signing this agreement, Wilexhas received approximately € 29.4 million ($ 39 million),€ 14.3 million ($ 19 million) upon signing and either€ 15.1 million ($ 20 million) after twelve months or alternativelythe European commercial rights for an undisclosedproduct from Prometheus. In addition WILEX willreceive milestone payments and royalties on US net salesof RENCAREX ® . Furthermore Prometheus will co-fund aportion of the ongoing development of RENCAREX ® .Another licensing deal was closed at the end of year 2011.Sanofi has exclusively licensed Scil Technology’s programfor the regenerative treatment of osteoarthritis andcartilage disorders. This deal is valued with more than€ 180 million and includes upfront payments, potentialmilestone payments and undisclosed royalties on worldwideproduct sales.These adds up to a record deal-closing of nearly € 1,4billion in 2011 – a strong argument for the attractivenessof Bavarian biotechnology!23
Page 2 and 3: Our research benefits your health.T
Page 4 and 5: ImprintEditorial staff: Georg Kää
Page 6 and 7: Select IMGM as your outsourcing par
Page 8 and 9: The 2011 Biotech Year in Bavaria -A
Page 10 and 11: Due to this focus that was establis
Page 12 and 13: Furthermore, the continued interest
Page 14 and 15: Last but not least, the IZB start-u
Page 16 and 17: Company FoundationsMerck-Sharp & Do
Page 18 and 19: Total number of employees in the Ba
Page 20 and 21: PHASE II4SC: Hepatocellular carcino
Page 24 and 25: M&A-ActivityIn early 2011 the acqui
Page 26: Due to the increasing number of new
Page 29: one so called “innovation allianc
Page 32 and 33: 4SC AGBIOTECH THERAPEUTICS & DIAGNO
Page 34 and 35: Contact:Dr. Luc St-OngeFraunhoferst
Page 36 and 37: Contact:Dr. Lars WassillWerkstr. 2D
Page 38 and 39: Apceth GmbH & Co. KGBIOTECH THERAPE
Page 40 and 41: Contact:Dr. Gundel HagerBahnhofstr.
Page 42 and 43: Bernina Plus GmbHBIOTECH THERAPEUTI
Page 44 and 45: Biontex Laboratories GmbHBIOTECH DE
Page 46 and 47: Carl Zeiss MicroImaging GmbHBIOTECH
Page 48 and 49: ChemDiv, Inc.CROContact:Dr. Anna Ni
Page 50 and 51: conoGenetix biosciences GmbHBIOTECH
Page 52 and 53: CoreLab Partners Europe GmbHCROCont
Page 54 and 55: Davids Biotechnologie GmbHBIOTECH D
Page 56 and 57: Dynamic BiosensorsBIOTECH DNA/PROTE
Page 58 and 59: Contact:Uschi LangGoethestr. 4D-803
Page 60 and 61: Eurofins MWG OperonBIOTECH DNA/PROT
Page 62 and 63: FGK Clinical Research GmbHCROContac
Page 64 and 65: GeneArt AGBIOTECHContact:Prof. Dr.
Page 66 and 67: Contact:Dr. Korbinian GroteBayerstr
Page 68 and 69: Contact:Peter Paul SchikoraMühlfel
Page 70 and 71: Contact:Kurt MartinJosef-Engert-Str
Page 72 and 73:
ibidi GmbHBIOTECH DEVICES & REAGENT
Page 74 and 75:
Immumed GmbH -Gesellschaft für ang
Page 76 and 77:
INHECO GmbHBIOTECH DEVICES & REAGEN
Page 78 and 79:
IRIS Biotech GmbHPHARMA & CHEMICAL
Page 80 and 81:
KLIFOVET AGCROContact:Dr. Klaus Hel
Page 82 and 83:
LEUKOCARE AGBIOTECH DEVICES & REAGE
Page 84 and 85:
medicomp GmbHCROContact:Dr. med. ve
Page 86 and 87:
Contact:Dr. Erwin SoutschekFlorians
Page 88 and 89:
MLL Münchner Leukämie Labor GmbHB
Page 90 and 91:
multimmune GmbHBIOTECH THERAPEUTICS
Page 92 and 93:
NanoScape AGPHARMA & CHEMICAL INDUS
Page 94 and 95:
nexttec GmbHBIOTECH DNA/PROTEIN ANA
Page 96 and 97:
Contact:Michael AlmstetterAm Klopfe
Page 98 and 99:
PAN Biotech GmbHBIOTECH DEVICES & R
Page 100 and 101:
Pharma Stulln GmbHPHARMA & CHEMICAL
Page 102 and 103:
Phytochem Referenzsubstanzen GbRmbH
Page 104 and 105:
PreSens Precision Sensing GmbHBIOTE
Page 106 and 107:
Contact:Dr. Torsten NeuefeindBunsen
Page 108 and 109:
Ridom GmbHBIOTECH BIOINFORMATICSCon
Page 110 and 111:
SERVIER Deutschland GmbHPHARMA & CH
Page 112 and 113:
SSS International Clinical Research
Page 114 and 115:
TILL Photonics GmbHBIOTECH DEVICES
Page 116 and 117:
Tripos InternationalBIOTECH BIOINFO
Page 118 and 119:
vertis Biotechnologie AGBIOTECH DNA
Page 120 and 121:
Wilex AGBIOTECH THERAPEUTICS & DIAG
Page 124:
Where the future becomes realityHOT
show all

Bavarian Biotech Report 2011/2012 (7MB) - Bio M

Create successful ePaper yourself

Delete template?

Save as template?